Telix_Main_Logo (3).png
Telix Announces Planned Registered Public Offering and Listing in the United States
January 04, 2024 16:59 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX, “Telix” or the “Company”) today announces that it is considering an initial public offering (“IPO”) of...
Telix_Main_Logo (3).png
Telix to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 16:55 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia, Jan. 03, 2024 (GLOBE NEWSWIRE) --  Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that Dr Christian Behrenbruch, Managing Director and Group CEO,...
20170406 Telix Logo.png
Telix Radiopharmaceutical Production Facility Buildout Commences
March 21, 2022 18:41 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia and BRUSSELS, Belgium, March 22, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to provide a material update on the development...
20170406 Telix Logo.png
EAU Updates Guidance for PSMA-PET Imaging
March 21, 2022 01:28 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia and LIÈGE, Belgium, March 21, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) welcomes the updated 2022 ‘Guidelines on Prostate...
20170406 Telix Logo.png
ZIRCON Phase III Kidney Cancer Imaging Study Completes Target Enrolment
March 07, 2022 17:37 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia, March 08, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, “Telix”, the “Company”) today announces that ZIRCON (Zirconium in Renal Cancer Oncology,...
20170406 Telix Logo.png
Telix Enters Commercial Distribution Agreement for Illuccix® in Australia
February 15, 2022 17:39 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into a commercial distribution agreement with...
20170406 Telix Logo.png
Telix and SHINE partner for Lutetium-177 Supply
February 10, 2022 16:09 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a new global clinical supply agreement with...
20170406 Telix Logo.png
Telix Expands Lutetium-177 Network with Eckert & Ziegler Clinical Supply Agreement
February 08, 2022 17:27 ET | Telix Pharmaceuticals Limited
MELBOURNE and LIEGE, Belgium, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a global clinical supply agreement with Berlin-based...
20170406 Telix Logo.png
Japanese Prostate Cancer Imaging Trial Meets Study Objectives
February 07, 2022 18:08 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia and KYOTO, Japan, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) in collaboration with Kanazawa University today announces that...
20170406 Telix Logo.png
Telix and Biokosmos Sign Distribution Agreement for Prostate Cancer Imaging in Greece and Cyprus
January 27, 2022 16:41 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia and ATHENS, Greece, Jan. 28, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an exclusive...